Figure 6: Biomarker profiles in the studied cohort and its composite analysis. A) PCA analysis of the whole cohort with the most informative biomarkers (CCL17, CCL13, CCL22, CCL27, E-Selectin, BDNF, CD25s, Notch1). B) Radar plots depicting changes in median values of each scaled biomarker between AD, psoriasis patients, and healthy individuals. C)-D) Ratios of best performing predictive biomarkers of a good response to dupilumab therapy E) Receiver Operating Characteristic (ROC) in a random forest model predicting good response (high and super responders vs. low responders) to dupilumab based on initial biomarkers with 2 best predictors (CCL17 to E-selectin and Notch1 to CD25s ratios - black curve) compared to models including CCL17 and E-selectin (red curve), Notch1 and CD25s (blue curve) or Notch1, CD25s, CCL17, E-Selectin (green curve).